PMID- 32296636
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 10
DP  - 2020
TI  - Expression Profile and Prognostic Values of HOXA Family Members in Laryngeal 
      Squamous Cell Cancer.
PG  - 368
LID - 10.3389/fonc.2020.00368 [doi]
LID - 368
AB  - The homeobox A cluster (HOXA) gene family, comprising 11 members, is involved in 
      a wide spectrum of biological functions in human cancers. However, there is 
      little research on the expression profile and prognostic values of HOXA genes in 
      laryngeal squamous cell cancer (LSCC). Based on updated public resources and 
      integrative bioinformatics analysis, we assessed the expression profile and 
      prognostic values of the HOXA family members. Expression and methylation data on 
      HOXA family members were obtained from The Cancer Genome Atlas (TCGA). The 
      prognostic values of HOXA members and clinical features were identified. A gene 
      set enrichment analysis (GSEA) was conducted to explore the mechanism underlying 
      the involvement of HOXA members in LSCC. The associations between tumor immune 
      infiltrating cells (TIICs) and the HOXA family members were evaluated using the 
      Tumor Immune Estimation Resource (TIMER) database. HOXA2 and HOXA4 were 
      downregulated and HOXA7 and HOXA9-13 were upregulated in LSCC. Upregulation of 
      HOXA10, HOXA11, and HOXA13, along with two clinical characteristics (M stage and 
      gender), were associated with a poor LSCC prognosis based on the results of 
      univariate and multivariate Cox proportional hazards regression analyses. 
      Although there were no significant correlations between TIICs and HOXA members, 
      the GSEA results indicated that HOXA members participate in multiple biological 
      processes underlying tumorigenesis. This study comprehensively analyzed the HOXA 
      members, providing insights for further investigation of the HOXA family members 
      as potential targets in LSCC.
CI  - Copyright (c) 2020 Li, Ye and Zhou.
FAU - Li, Jinyun
AU  - Li J
AD  - Department of Oncology and Hematology, The Affiliated Hospital of Medical School 
      of Ningbo University, Ningbo, China.
FAU - Ye, Meng
AU  - Ye M
AD  - Department of Oncology and Hematology, The Affiliated Hospital of Medical School 
      of Ningbo University, Ningbo, China.
FAU - Zhou, Chongchang
AU  - Zhou C
AD  - Department of Otorhinolaryngology Head and Neck Surgery, Ningbo Medical Center 
      Lihuili Hospital, Ningbo, China.
LA  - eng
PT  - Journal Article
DEP - 20200331
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC7136465
OTO - NOTNLM
OT  - GSEA
OT  - HOXA family
OT  - LSCC
OT  - TCGA
OT  - prognosis
EDAT- 2020/04/17 06:00
MHDA- 2020/04/17 06:01
PMCR- 2020/01/01
CRDT- 2020/04/17 06:00
PHST- 2019/11/29 00:00 [received]
PHST- 2020/03/02 00:00 [accepted]
PHST- 2020/04/17 06:00 [entrez]
PHST- 2020/04/17 06:00 [pubmed]
PHST- 2020/04/17 06:01 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2020.00368 [doi]
PST - epublish
SO  - Front Oncol. 2020 Mar 31;10:368. doi: 10.3389/fonc.2020.00368. eCollection 2020.